The Rosette Eye: the key transition phase in the birth of a massive star

Massive protostars dramatically influence their surroundings via accretion-induced outflows and intense radiation fields. They evolve rapidly, the disk and infalling envelope being evaporated and dissipated in $\sim$ 10$^5$ years. Consequently, they are very rare and investigating this important phase of early stellar evolution is extremely difficult. Here we present the discovery of a key transient phase in the emergence of a massive young star, in which ultraviolet radiation from the new-born giant has just punctured through its natal core. The massive young stellar object AFGL 961 II is readily resolved in the near infrared. Its morphology closely resembles a cat's eye and is here dubbed as the Rosette Eye. Emerging ionized flows blow out an hourglass shaped nebula, which, along with the existence of strong near-infrared excess, suggests the existence of an accretion disk in the perpendicular direction. The lobes of the hourglass, however, are capped with arcs of static H$_{2}$ emission produced by fluorescence. This study has strong implications for our understanding of how massive stars embark on their formation.Comment: 3 figure

A Sample of Very Young Field L Dwarfs and Implications for the Brown Dwarf "Lithium Test" at Early Ages

Using a large sample of optical spectra of late-type dwarfs, we identify a subset of late-M through L field dwarfs that, because of the presence of low-gravity features in their spectra, are believed to be unusually young. From a combined sample of 303 field L dwarfs, we find observationally that 7.6+/-1.6% are younger than 100 Myr. This percentage is in agreement with theoretical predictions once observing biases are taken into account. We find that these young L dwarfs tend to fall in the southern hemisphere (Dec < 0 deg) and may be previously unrecognized, low-mass members of nearby, young associations like Tucana-Horologium, TW Hydrae, beta Pictoris, and AB Doradus. We use a homogeneously observed sample of roughly one hundred and fifty 6300-10000 Angstrom spectra of L and T dwarfs taken with the Low-Resolution Imaging Spectrometer at the W. M. Keck Observatory to examine the strength of the 6708-A Li I line as a function of spectral type and further corroborate the trends noted by Kirkpatrick et al. (2000). We use our low-gravity spectra to investigate the strength of the Li I line as a function of age. The data weakly suggest that for early- to mid-L dwarfs the line strength reaches a maximum for a few 100 Myr, whereas for much older (few Gyr) and much younger (<100 Myr) L dwarfs the line is weaker or undetectable. We show that a weakening of lithium at lower gravities is predicted by model atmosphere calculations, an effect partially corroborated by existing observational data. Larger samples containing L dwarfs of well determined ages are needed to further test this empirically. If verified, this result would reinforce the caveat first cited in Kirkpatrick et al. (2006) that the lithium test should be used with caution when attempting to confirm the substellar nature of the youngest brown dwarfs.Comment: 73 pages with 22 figures; to appear in ApJ (Dec 20, 2008, v689n2 issue

NASA SpaceCube Next-Generation Artificial-Intelligence Computing for STP-H9-SCENIC on ISS

Recently, Artificial Intelligence (AI) and Machine Learning (ML) capabilities have seen an exponential increase in interest from academia and industry that can be a disruptive, transformative development for future missions. Specifically, AI/ML concepts for edge computing can be integrated into future missions for autonomous operation, constellation missions, and onboard data analysis. However, using commercial AI software frameworks onboard spacecraft is challenging because traditional radiation-hardened processors and common spacecraft processors cannot provide the necessary onboard processing capability to effectively deploy complex AI models. Advantageously, embedded AI microchips being developed for the mobile market demonstrate remarkable capability and follow similar size, weight, and power constraints that could be imposed on a space-based system. Unfortunately, many of these devices have not been qualified for use in space. Therefore, Space Test Program - Houston 9 - SpaceCube Edge-Node Intelligent Collaboration (STP-H9-SCENIC) will demonstrate inflight, cutting-edge AI applications on multiple space-based devices for next-generation onboard intelligence. SCENIC will characterize several embedded AI devices in a relevant space environment and will provide NASA and DoD with flight heritage data and lessons learned for developers seeking to enable AI/ML on future missions. Finally, SCENIC also includes new CubeSat form-factor GPS and SDR cards for guidance and navigation

Three’s Company: An Additional Non-transiting Super-Earth in the Bright HD 3167 System, and Masses for All Three Planets

HD 3167 is a bright (V = 8.9), nearby K0 star observed by the NASA K2 mission (EPIC 220383386), hosting two small, short-period transiting planets. Here we present the results of a multi-site, multi-instrument radial velocity campaign to characterize the HD 3167 system. The masses of the transiting planets are 5.02±0.38 MEarth for HD 3167 b, a hot super-Earth with a likely rocky composition (ρb = 5.60+2.15-1.43g cm-3), and 9.80+1.30-1.24 MEarth for HD 3167 c, a warm sub-Neptune with a likely substantial volatile complement (ρc = 1.97+0.94-0.59 g cm-3). We explore the possibility of atmospheric composition analysis and determine that planet c is amenable to transmission spectroscopy measurements, and planet b is a potential thermal emission target. We detect a third, non-transiting planet, HD 3167 d, with a period of 8.509+/-0.045 d (between planets b and c) and a minimum mass of 6.90±0.71 MEarth. We are able to constrain the mutual inclination of planet d with planets b and c: we rule out mutual inclinations below 1.3 degrees as we do not observe transits of planet d. From 1.3-40 degrees, there are viewing geometries invoking special nodal configurations which result in planet d not transiting some fraction of the time. From 40-60 degrees, Kozai-Lidov oscillations increase the system's instability, but it can remain stable for up to 100Myr. Above 60 degrees, the system is unstable. HD 3167 promises to be a fruitful system for further study and a preview of the many exciting systems expected from the upcoming NASATESS mission.Publisher PDFPeer reviewe

Control of Equine Infectious Anemia Virus Is Not Dependent on ADCC Mediating Antibodies

AbstractHorses infected with equine infectious anemia virus (EIAV) have recurrent episodes of viremia which are eventually controlled, but the immune mechanisms have not been identified. Antibodies were detected to the surface of EIAV-infected cells within 1 month postinfection and remained for at least 3.5 years postinfection. These antibodies recognized cell surface-exposed envelope (Env) glycoproteins, but could not mediate antibody dependent cellular cytotoxicity (ADCC) using EIAV-WSU5-infected equine kidney (EK) cells as targets and peripheral blood mononuclear cells (PBMC) or polymorphonuclear cells (PMN) as effector cells. Furthermore, purified IgG antibodies from horses infected with either EIAV-WSU5 or EIAV-Wyo did not mediate ADCC of infected target cells. Armed effector cells could not be detected in infected horse blood nor could effector cells be prearmed by incubation with serum antibodies to cell surface antigens. The use of EIAV-WSU5-infected equine macrophages as target cells did not result in ADCC. In contrast, serum antibody from EHV-1 vaccinated horses and PBMC or PMN as effector cells caused ADCC of EHV-1-infected EK cells. These results indicate that ADCC is not involved in the control of EIAV in carrier horses

Major Histocompatibility Complex-Restricted CD8\u3csup\u3e+\u3c/sup\u3e Cytotoxic T Lymphocytes from Horses with Equine Infectious Anemia Virus Recognize Env and Gag/PR Proteins

Cytotoxic T lymphocytes (CTL) can control some viral infections and may be important in the control of lentiviruses, including human immunodeficiency virus type 1. Since there is limited evidence for an in vivo role of CTL in control of lentiviruses, dissection of immune mechanisms in animal lentiviral infections may provide needed information. Horses infected with equine infectious anemia virus (EIAV), a lentivirus, have acute plasma viremia which is terminated in immunocompetent horses. Viremic episodes may recur, but most horses ultimately control infection and become asymptomatic carriers. To begin dissection of the immune mechanisms involved in EIAV control, peripheral blood mononuclear cells (PBMC) from infected horses were evaluated for CTL to EIAV-infected cells. By using noninfected and EIAV-infected autologous equine kidney (EK) cells in Cr-release assays, EIAV-specific cytotoxic activity was detected in unstimulated PBMC from three infected horses. The EIAV-specific cytotoxic activity was major histocompatibility complex (MHC) restricted, as determined by assaying EIAV-infected heterologous EK targets, and was mediated by CD8+ T lymphocytes, as determined by depleting these cells by a panning procedure with an anti-CD8 monoclonal antibody. MHC-restricted CD8+ CTL in unstimulated PBMC from infected horses caused significant specific lysis of autologous EK cells infected with recombinant vaccinia viruses expressing EIAV genes, either env or gag plus 5\u27 pol. The EIAV-specific MHC-restricted CD8+ CTL were detected in two EIAV-infected horses within a few days after plasma viremia occurred and were present after viremia was terminated. The detection of these immune effector cells in EIAV-infected horses permits further studies to determine their in vivo role

Cloning and large-scale expansion of epitope-specific equine cytotoxic T lymphocytes using an anti-equine CD3 monoclonal antibody and human recombinant IL-2

Cytotoxic T lymphocytes are involved in controlling intracellular pathogens in many species, including horses. Particularly, CTL are critical for the control of equine infectious anemia virus (EIAV), a lentivirus that infects horses world-wide. In humans and animal models, CTL clones are valuable for evaluating the fine specificity of epitope recognition, and for adoptive immunotherapy against infectious and neoplastic diseases. Cloned CTL would be equally useful for similar studies in the horse. Here we present the first analysis of a method to generate equine CTL clones. Peripheral blood mononuclear cells were obtained from an EIAV-infected horse and stimulated with the EIAV Rev-QW11 peptide. Sorted CD8+ T cells were cloned by limiting dilution, and expanded without further antigen addition using irradiated PBMC, anti-equine CD3, and human recombinant IL-2. Clones could be frozen and thawed without detrimental effects, and could be subsequently expanded to numbers exceeding 2 × 10 9 cells. Flow cytometry of expanded clones confirmed the CD3+/CD8+ phenotype, and chromium release assays confirmed CTL activity. Finally, sequencing TCR beta chain genes confirmed clonality. Our results provide a reliable means to generate large numbers of epitope-specific equine CTL clones that are suitable for use in downstream applications, including functional assays and adoptive transfer studies

Failure of low-dose recombinant human IL-2 to support the survival of virus-specific CTL clones infused into severe combined immunodeficient foals: Lack of correlation between in vitro activity and in vivo efficacy

Although CTL are important for control of lentiviruses, including equine infectious anemia virus (EIAV), it is not known if CTL can limit lentiviral replication in the absence of CD4 help and neutralizing antibody. Adoptive transfer of EIAV-specific CTL clones into severe combined immunodeficient (SCID) foals could resolve this issue, but it is not known whether exogenous IL-2 administration is sufficient to support the engraftment and proliferation of CTL clones infused into immunodeficient horses. To address this question we adoptively transferred EIAV Rev-specific CTL clones into four EIAV-challenged SCID foals, concurrent with low-dose aldesleukin (180,000 U/m 2), a modified recombinant human IL-2 (rhuIL-2) product. The dose was calculated based on the specific activity on equine PBMC in vitro, and resulted in plasma concentrations considered sufficient to saturate high affinity IL-2 receptors in humans. Despite specific activity on equine PBMC that was equivalent to recombinant equine IL-2 and another form of rhuIL-2, aldesleukin did not support the engraftment and expansion of infused CTL clones, and control of viral load and clinical disease did not occur. It was concluded that survival of Rev-specific CTL clones infused into EIAV-challenged SCID foals was not enhanced by aldesleukin at the doses used in this study, and that in vitro specific activity did not correlate with in vivo efficacy. Successful adoptive immunotherapy with CTL clones in immunodeficient horses will likely require higher doses of rhuIL-2, co-infusion of CD4+ T lymphocytes, or administration of equine IL-2